Truist Securities Maintains Buy on Eli Lilly, Raises Price Target to $850
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas maintains a Buy rating on Eli Lilly (LLY) and increases the price target from $650 to $850, indicating a positive outlook on the company's stock.
February 07, 2024 | 9:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has maintained a Buy rating on Eli Lilly and raised the price target from $650 to $850, showing strong confidence in the company's future performance.
The increase in price target by a significant margin from $650 to $850 by Truist Securities reflects a strong bullish sentiment towards Eli Lilly's stock. This adjustment suggests that the analyst sees substantial growth potential or positive developments in the company's future, which could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100